Cargando…
The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment
SIMPLE SUMMARY: YAP/TAZ are the central effectors of the Hippo pathway and orchestrate their oncogenic program by binding to TEAD transcriptional factors. Here, we document a comprehensive understanding of how YAP/TAZ dependent tumors could be exploited for improving cancer therapies. Aside from pro...
Autores principales: | Mokhtari, Reza Bayat, Ashayeri, Neda, Baghaie, Leili, Sambi, Manpreet, Satari, Kosar, Baluch, Narges, Bosykh, Dmitriy A., Szewczuk, Myron R., Chakraborty, Sayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340833/ https://www.ncbi.nlm.nih.gov/pubmed/37444578 http://dx.doi.org/10.3390/cancers15133468 |
Ejemplares similares
-
A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy
por: Pobbati, Ajaybabu V., et al.
Publicado: (2020) -
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
por: Cunningham, Richard, et al.
Publicado: (2022) -
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021) -
The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis
por: Zinatizadeh, Mohammad Reza, et al.
Publicado: (2019) -
Hippo-YAP/TAZ signaling in angiogenesis
por: Park, Jeong Ae, et al.
Publicado: (2018)